Potential Effects of Fluticasone Propionate on Bone Mineral Density in Patients With Asthma: A 2-Year Randomized, Double-Blind, Placebo-Controlled Trial

Kemp, James P.; Osur, Scott L.; Shrewsbury, Stephen B.; Herje, Nancy; Duke, Susan P.; Harding, S. M.; Faulkner, Kenneth G.; Crim, Courtney

doi:10.4065/79.4.458

Cited by 36 publications

(16 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To minimize possible bias, technicians who took BMD measurements were blinded with respect to the treatment given. BMD results from this study corroborate those of Kemp et al [27], i.e. that even the most commonly bioavailable formulation of FP at a relatively high dose does not cause reduced BMD in the lumbar spine, the most appropriate and sensitive marker for the skeletal effects of systemic corticosteroid therapy.…”

Section: Discussionsupporting

confidence: 81%

Osteocalcin, Cortisol Levels, and Bone Mineral Density in Prepubertal Children with Asthma Treated with Long-Term Fluticasone Propionate

et al. 2012

View full text Add to dashboard Cite

Aims: The objective of this study is to determine the effects of the long-term treatment with inhaled fluticasone propionate on osteocalcin, cortisol levels, and bone mineral status in children with asthma. Methods: This cross-sectional study examined 230 prepubertal children with asthma (aged 6–11) who had intermittently used inhaled fluticasone propionate for at least 5 years at a mean daily dose of 200 µg (range: 200–350 µg). Serum osteocalcin, cortisol, and bone mineral density (BMD) of the lumbar spine were obtained from each participant. The control group consisted of gender- and age-matched children (n = 170) who were newly diagnosed with asthma and who were not being treated with corticosteroid. Results: The average age (±SEM) was 8.9 ± 0.7 years, their mean (±SEM) daily steroid dose was 180.3 ± 55.0 µg, with 236.5 ± 17.2 g total steroid use during treatment. Between the study and the control groups, no significant differences were observed in cortisol, osteocalcin levels, and BMD (p > 0.05). Conclusion: Long-term treatment with inhaled fluticasone propionate (100 µg twice daily) revealed no negative effects on serum osteocalcin, cortisol levels, and BMD in children with asthma.

show abstract

Section: Discussionsupporting

confidence: 81%

Osteocalcin, Cortisol Levels, and Bone Mineral Density in Prepubertal Children with Asthma Treated with Long-Term Fluticasone Propionate

et al. 2012

View full text Add to dashboard Cite

show abstract

“…The conclusions from several studies [52,149,[160][161][162][163][164][165][166] are summarised in table 7.…”

Section: Inhaled Glucocorticosteroidsmentioning

confidence: 99%

Global strategy for asthma management and prevention: GINA executive summary

Bateman

Ss²,

Barnes³

et al. 2007

Eur Respir J

2,666

2,301

View full text Add to dashboard Cite

Asthma is a serious health problem throughout the world. During the past two decades, many scientific advances have improved our understanding of asthma and ability to manage and control it effectively. However, recommendations for asthma care need to be adapted to local conditions, resources and services. Since it was formed in 1993, the Global Initiative for Asthma, a network of individuals, organisations and public health officials, has played a leading role in disseminating information about the care of patients with asthma based on a process of continuous review of published scientific investigations. A comprehensive workshop report entitled ''A Global Strategy for Asthma Management and Prevention'', first published in 1995, has been widely adopted, translated and reproduced, and forms the basis for many national guidelines. The 2006 report contains important new themes. First, it asserts that ''it is reasonable to expect that in most patients with asthma, control of the disease can and should be achieved and maintained,'' and recommends a change in approach to asthma management, with asthma control, rather than asthma severity, being the focus of treatment decisions. The importance of the patient-care giver partnership and guided self-management, along with setting goals for treatment, are also emphasised.

show abstract

“…All changes in 24-hour urinary cortisol values over the 12-week treatment period were within the same range for patients treated with fluticasone propionate as in patients treated with placebo with the exception that two fluticasone propionate patients (one low-dose, 88 µg bid; and one high-dose, 440 µg bid) had increases in cortisol excretion rates compared with baseline greater than any of the patients in the placebo group. In previous studies in which patients with asthma used non-HFA formulations of fluticasone propionate at daily doses of up to 1,000 µg for up to 2 years (15,16), effects on HPA-axis function, bone mineral density, and eyes were comparable to those in patients who received placebo.…”

Section: Discussionmentioning

confidence: 54%

Fluticasone Propionate HFA-134a Pressurized Metered-Dose Inhaler in Adolescents and Adults with Moderate to Severe Asthma

et al. 2005

Self Cite

View full text Add to dashboard Cite

In this randomized, double-blind, placebo-controlled trial, 397 patients with moderate to severe asthma, previously treated with bronchodilators alone, received fluticasone propionate 88, 220, or 440 microg twice daily, or placebo via metered dose inhaler (MDI) for 12 weeks. Mean change from baseline to endpoint in pre-dose percent predicted forced expiratory volume in one second (FEV1) was greater (p < 0.001) in each fluticasone propionate group (9.0%, 88 microg bid; 9.8%, 220 microg bid; 11.2%, 440 microg bid) versus placebo (3.4%). Morning and evening peak expiratory flow (PEF), asthma symptoms, and supplemental albuterol use also improved in all fluticasone propionate groups versus placebo. The incidence of adverse events and 24-hour urine cortisol excretion rates were similar between active treatments and placebo.

show abstract

Potential Effects of Fluticasone Propionate on Bone Mineral Density in Patients With Asthma: A 2-Year Randomized, Double-Blind, Placebo-Controlled Trial

Cited by 36 publications

References 35 publications

Osteocalcin, Cortisol Levels, and Bone Mineral Density in Prepubertal Children with Asthma Treated with Long-Term Fluticasone Propionate

Osteocalcin, Cortisol Levels, and Bone Mineral Density in Prepubertal Children with Asthma Treated with Long-Term Fluticasone Propionate

Global strategy for asthma management and prevention: GINA executive summary

Fluticasone Propionate HFA-134a Pressurized Metered-Dose Inhaler in Adolescents and Adults with Moderate to Severe Asthma

Contact Info

Product

Resources

About